Singapore, Oct. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Mo... Read More
U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07855575) titled 'Optimizing the Paracetamol Dose for Prevention of Post-Spinal Shivering in Lower Limb Orthop... Read More
Singapore, Oct. 3 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in... Read More
Singapore, Oct. 3 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in... Read More
Singapore, Oct. 3 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and e... Read More
Singapore, Oct. 3 -- The Health Sciences Authority received information related to the study titled 'A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of ascimi... Read More
Singapore, Oct. 3 -- The Health Sciences Authority received information related to the study titled 'A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with ... Read More
Singapore, Oct. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy v... Read More
U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07854951) titled 'Hypnosis for Pain and Nausea Reduction in Scoliosis Surgery: An Interventional Study' on Dec... Read More
Singapore, Oct. 3 -- The Health Sciences Authority received information related to the study titled 'CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitaxel... Read More